https://www.yiliao.com/index.php?action=history&feed=atom&title=%E9%9D%B6%E5%90%91%E8%8D%AF
靶向药 - 版本历史
2026-04-17T17:54:48Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=%E9%9D%B6%E5%90%91%E8%8D%AF&diff=315678&oldid=prev
185.180.13.100：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-25T16:01:01Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>靶向治疗</strong>（Targeted Therapy），又称<strong>分子靶向药物</strong>，是现代肿瘤精准医疗（Precision Medicine）的基石。与传统<strong>[[化疗]]</strong>（Chemotherapy）“杀敌一千，自损八百”的细胞毒性机制不同，靶向药利用肿瘤细胞与正常细胞在分子生物学上的差异，针对特定的<strong>“驱动基因”</strong>（如 EGFR, ALK, HER2）或其蛋白产物进行“精确制导”打击。这种治疗模式就像一把“钥匙”只开一把“锁”，能够特异性地阻断肿瘤生长的信号通路，从而诱导癌细胞凋亡，同时最大程度地减少对正常组织的损伤。自 2001 年<strong>[[伊马替尼]]</strong>（格列卫）获批以来，靶向药已将许多曾经的“绝症”（如晚期肺腺癌、慢粒白血病）转化为可长期控制的<strong>慢性病</strong>。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">Targeted Therapy</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Precision Medicine Cornerstone (点击展开)</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
[[Image:Lock_and_Key_Mechanism.png|100px|锁钥机制示意图]]<br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">生物导弹 (Guided Missile)</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">核心策略</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">抑制特定致癌通路</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">主要类型</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">小分子 (TKI, -ib)<br>单克隆抗体 (mAb, -mab)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">必要条件</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;"><strong>[[基因检测]]</strong> (Biomarker)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">代表药物</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">伊马替尼, 奥希替尼<br>曲妥珠单抗</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">主要局限</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #b91c1c;"><strong>[[耐药性]]</strong> (Resistance)<br>靶点稀缺</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">未来形态</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;"><strong>[[ADC]]</strong> (偶联药物)<br>PROTAC</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">药理机制：锁与钥的匹配</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
靶向药的研发基于对肿瘤分子生物学的深刻理解，主要分为两大阵营：<br />
</p><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>小分子抑制剂 (Small Molecules)：</strong><br />
<br>通常以“<strong>-替尼</strong>”(-tinib) 结尾。它们的分子量极小，能够穿透细胞膜进入细胞内部。它们主要结合在胞内激酶域的 ATP 结合口袋上，通过竞争性占位，阻断磷酸基团的转移，从而切断细胞增殖的“电源”信号（如 <strong>[[EGFR-TKI]]</strong>）。</li><br />
<li style="margin-bottom: 12px;"><strong>单克隆抗体 (Monoclonal Antibodies)：</strong><br />
<br>通常以“<strong>-单抗</strong>”(-mab) 结尾。它们是大分子蛋白质，无法进入细胞，主要结合在细胞表面的受体或循环中的配体上（如 <strong>[[VEGF]]</strong>）。除了阻断信号，抗体还能标记癌细胞，招募免疫系统进行杀伤（ADCC 效应）。</li><br />
</ul><br />
<br />
<h2 style="background: #fff1f2; color: #9f1239; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #9f1239; font-weight: bold;">临床全景：两大阵营的较量</h2><br />
<div style="background-color: #fff5f5; border-left: 5px solid #e11d48; padding: 15px 20px; margin: 20px 0; border-radius: 4px;"><br />
<h3 style="margin-top: 0; color: #be123c; font-size: 1.1em;">没有靶点，就没有靶向</h3><br />
<p style="margin-bottom: 0; text-align: justify; font-size: 0.95em; color: #334155;"><br />
靶向治疗的第一原则是“精准检测”。盲试靶向药不仅无效（如 EGFR 野生型肺癌吃易瑞沙），反而可能因为副作用和延误治疗而有害。<br />
</p><br />
</div><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.95em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 20%;">特征</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af; width: 40%;">小分子抑制剂 (TKI)</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #9f1239; width: 40%;">单克隆抗体 (mAb)</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">给药方式</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>口服</strong> (Pill)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>静脉注射</strong> (IV) / 皮下</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">作用位点</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">胞内 (Intracellular)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">胞外 / 跨膜蛋白</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">半衰期</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">短 (小时级)，需每日服药</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">长 (周级)，2-3周一次</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">穿透性</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">好，新一代药物可穿透<strong>[[血脑屏障]]</strong></td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">差，难以入脑</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">代表药物</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">吉非替尼, 奥希替尼, 洛拉替尼</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">曲妥珠单抗, 贝伐珠单抗, 西妥昔单抗</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Druker BJ, Talpaz M, Resta DJ, et al. (2001).</strong> <em>Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.</em> <strong>[[New England Journal of Medicine]]</strong>. 2001;344(14):1031-1037.<br><br />
<span style="color: #475569;">[划时代突破]：报道了伊马替尼（格列卫）在慢粒白血病中的惊人疗效，标志着人类攻克癌症进入了靶向治疗的新纪元。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Lynch TJ, Bell DW, Sordella R, et al. (2004).</strong> <em>Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.</em> <strong>[[New England Journal of Medicine]]</strong>. 2004;350(21):2129-2139.<br><br />
<span style="color: #475569;">[肺癌里程碑]：发现了 EGFR 敏感突变是吉非替尼（易瑞沙）起效的根本原因，开启了实体瘤基于基因分型进行精准治疗的时代。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[3] <strong>Slamon DJ, Leyland-Jones B, Shak S, et al. (2001).</strong> <em>Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.</em> <strong>[[New England Journal of Medicine]]</strong>. 2001;344(11):783-792.<br><br />
<span style="color: #475569;">[抗体药物]：证明了曲妥珠单抗（赫赛汀）改变了 HER2 阳性乳腺癌患者的自然病程，确立了单克隆抗体在实体瘤中的治疗地位。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
靶向治疗 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">对比概念</td><br />
<td style="padding: 10px 15px; color: #334155;"><strong>[[化疗]]</strong> (无差别杀伤) • <strong>[[免疫治疗]]</strong> (激活 T 细胞)</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">黄金靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">EGFR (肺癌) • HER2 (乳腺癌) • BCR-ABL (白血病) • BRAF</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">耐药模式</td><br />
<td style="padding: 10px 15px; color: #334155;">靶点突变 (如 T790M) • 旁路激活 (如 MET 扩增) • 表型转化</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">升级版本</td><br />
<td style="padding: 10px 15px; color: #334155;"><strong>[[ADC]]</strong> (抗体偶联药物)：将靶向的“导航”与化疗的“炸药”结合</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
185.180.13.100